These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32199547)

  • 21. Feasibility, Engagement, and Usability of a Remote, Smartphone-Based Contingency Management Program as a Treatment Add-On for Patients Who Use Methamphetamine: Single-Arm Pilot Study.
    Hallgren KA; Duncan MH; Iles-Shih MD; Cohn EB; McCabe CJ; Chang YM; Saxon AJ
    JMIR Form Res; 2023 Jul; 7():e47516. PubMed ID: 37410529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials.
    Amin-Esmaeili M; Farokhnia M; Susukida R; Leggio L; Johnson RM; Crum RM; Mojtabai R
    Addiction; 2024 May; 119(5):833-843. PubMed ID: 38197836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.
    Poling J; Oliveto A; Petry N; Sofuoglu M; Gonsai K; Gonzalez G; Martell B; Kosten TR
    Arch Gen Psychiatry; 2006 Feb; 63(2):219-28. PubMed ID: 16461866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond methamphetamine: Documenting the implementation of the Matrix model of substance use treatment for opioid users in a South African setting.
    Magidson JF; Gouse H; Burnhams W; Wu CY; Myers B; Joska JA; Carrico AW
    Addict Behav; 2017 Mar; 66():132-137. PubMed ID: 27940387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duration effects in contingency management treatment of methamphetamine disorders.
    Roll JM; Chudzynski J; Cameron JM; Howell DN; McPherson S
    Addict Behav; 2013 Sep; 38(9):2455-62. PubMed ID: 23708468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy.
    Silverman K; Higgins ST; Brooner RK; Montoya ID; Cone EJ; Schuster CR; Preston KL
    Arch Gen Psychiatry; 1996 May; 53(5):409-15. PubMed ID: 8624184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence.
    Cook R; Quinn B; Heinzerling K; Shoptaw S
    Addiction; 2017 Jun; 112(6):1077-1085. PubMed ID: 28107598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychosocial interventions for cannabis use disorder.
    Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets.
    Schmitz JM; Lindsay JA; Stotts AL; Green CE; Moeller FG
    Exp Clin Psychopharmacol; 2010 Jun; 18(3):238-44. PubMed ID: 20545388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An autoregressive cross-lagged model unraveling co-occurring stimulant use and HIV: Results from a randomized controlled trial.
    Lee JY; Lee JE; Moskowitz JT; Feaster DJ; Neilands TB; Dilworth SE; Rodriguez A; Carrico AW
    Drug Alcohol Depend; 2021 Aug; 225():108752. PubMed ID: 34144507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The reflections of health service providers on implementing contingency management for methamphetamine use disorder in Australia.
    Clay S; Wilkinson Z; Ginley M; Arunogiri S; Christmass M; Membrey D; MacCartney P; Sutherland R; Colledge-Frisby S; Marshall AD; Nagle J; Degenhardt L; Farrell M; McKetin R
    Drug Alcohol Rev; 2024 Jul; 43(5):1313-1322. PubMed ID: 38704742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cocaine abstinence during the "critical period" of a contingency management trial predicts future abstinence in people with cocaine use disorder.
    Regnier SD; Shellenberg TP; Koffarnus MN; Cox DH; Lile JA; Rush CR; Stoops WW
    Drug Alcohol Depend; 2023 Dec; 253():111030. PubMed ID: 38006674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decision-Making by Patients With Methamphetamine Use Disorder Receiving Contingency Management Treatment: Magnitude and Frequency Effects.
    Lake MT; Shoptaw S; Ipser JC; Takada S; van Nunen LJ; Lipinska G; Stein DJ; London ED
    Front Psychiatry; 2020; 11():22. PubMed ID: 32180733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men.
    Shoptaw S; Reback CJ; Peck JA; Yang X; Rotheram-Fuller E; Larkins S; Veniegas RC; Freese TE; Hucks-Ortiz C
    Drug Alcohol Depend; 2005 May; 78(2):125-34. PubMed ID: 15845315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contingent Vs. Non-Contingent Rewards: Time-Based Intervention Response Patterns Among Stimulant-Using Men Who Have Sex With Men.
    Shoptaw S; Landovitz RJ; Reback CJ
    J Subst Abuse Treat; 2017 Jan; 72():19-24. PubMed ID: 27938777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence.
    Brensilver M; Heinzerling KG; Swanson AN; Shoptaw SJ
    Exp Clin Psychopharmacol; 2012 Oct; 20(5):430-5. PubMed ID: 22867036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-label pilot study of modafinil for methamphetamine dependence.
    McGaugh J; Mancino MJ; Feldman Z; Chopra MP; Gentry WB; Cargile C; Oliveto A
    J Clin Psychopharmacol; 2009 Oct; 29(5):488-91. PubMed ID: 19745650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study.
    Peirce JM; Petry NM; Stitzer ML; Blaine J; Kellogg S; Satterfield F; Schwartz M; Krasnansky J; Pencer E; Silva-Vazquez L; Kirby KC; Royer-Malvestuto C; Roll JM; Cohen A; Copersino ML; Kolodner K; Li R
    Arch Gen Psychiatry; 2006 Feb; 63(2):201-8. PubMed ID: 16461864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A positive affect intervention alters leukocyte DNA methylation in sexual minority men with HIV who use methamphetamine.
    Carrico AW; Cherenack EM; Flentje A; Moskowitz JT; Asam K; Ghanooni D; Chavez JV; Neilands TB; Dilworth SE; Rubin LH; Gouse H; Fuchs D; Paul RH; Aouizerat BE
    Brain Behav Immun; 2024 Aug; 120():151-158. PubMed ID: 38777283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison between low-magnitude voucher and buprenorphine medication contingencies in promoting abstinence from opioids and cocaine.
    Gross A; Marsch LA; Badger GJ; Bickel WK
    Exp Clin Psychopharmacol; 2006 May; 14(2):148-56. PubMed ID: 16756418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.